Jeff Lu is CEO and Co-Founder of Engine Biosciences, which discovers and develops new precision medicines based on novel biology uncovered by its platform integrating next-generation CRISPR screening, machine learning, and drug discovery chemistry. Engine Bio identifies patient subpopulations defined by specific genetic mutations sensitizing cancers to certain drugs, and the company is advancing its pipeline of oncology therapeutics and biomarkers. Engine Bio is backed by US$80M in funding from blue chip investors across US and Asia.

Jeff is passionate about generating impact from new technology, data, and biotechnology. He serves as a co-founder of NSG Ventures, a biotech venture capital and venture building firm. He has helped build several companies through significant value creation, financings, and exits, including Enleofen (acquired by Boehringer Ingelheim), AAE (acquired by Expedia), PairX Bio, GDMC, and others. Earlier in his career, he led corporate and commercial strategy and data analytics at AirAsia and was a consultant at Bain & Company.